Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Inhibitor protein

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    499 result(s) found for: Inhibitor protein. Displaying page 1 of 25.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-006867-22 Sponsor Protocol Number: FNMPK012007 Start Date*: Information not available in EudraCT
    Sponsor Name:University Hospital Motol
    Full Title: Treatment of proteinuria with angiotensin-converting enzyme inhibitor in children after renal transplantation
    Medical condition: proteinuria and hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037032 Proteinuria LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-002672-95 Sponsor Protocol Number: UMCNONCO200801 Start Date*: 2008-07-29
    Sponsor Name:University Medical Centre Nijmegen St Radboud
    Full Title: Studie naar de optimale therapieduur van orale angiogenese remmers
    Medical condition: Patients with a metastatic malignancy, treated with a registered oral angiogenetic inhibitor (tyrosine kinase inhibitor), who have progressive disease according to RECIST on CT-evaluation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006579-41 Sponsor Protocol Number: ANG3070-CKD-201 Start Date*: 2022-03-07
    Sponsor Name:Angion Biomedica Corp.
    Full Title: A Phase 2, Multicenter, Double-Blind, Randomized, Placebo-controlled Study of Safety and Efficacy Of ANG-3070 in Patients with Primary Glomerular Disease and Persistent Proteinuria
    Medical condition: Primary glomerular disease and persistent proteinuria
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10037032 Proteinuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) ES (Prematurely Ended) BG (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-002509-13 Sponsor Protocol Number: 3475-183 Start Date*: 2016-02-25
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A phase III study of Pomalidomide and low dose Dexamethasone with or without Pembrolizumab (MK3475) in refractory or relapsed and refractory Multiple Myeloma (rrMM) (KEYNOTE 183)
    Medical condition: Patients with refractory or relapsed and refractory multiple myeloma (rrMM) who have failed at least 2 lines of prior treatment and have been previously exposed to an immunomodulatory drug (IMiDs) ...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) NO (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002023-15 Sponsor Protocol Number: EFC16293 Start Date*: 2020-02-25
    Sponsor Name:Bioverativ Therapeutics Inc. (a Sanofi company)
    Full Title: Phase 3 Open-Label, Multicenter Study of the Safety, Efficacy, and Pharmacokinetics of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein (rFVIIIFc-VWF-XTE...
    Medical condition: severe hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10016080 Factor VIII deficiency PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) FR (Completed) BG (Completed) BE (Completed) GR (Completed) HU (Completed) NL (Completed) ES (Completed) Outside EU/EEA IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000769-18 Sponsor Protocol Number: EFC16295 Start Date*: Information not available in EudraCT
    Sponsor Name:Bioverativ Therapeutics Inc.
    Full Title: A Phase 3 open-label, multicenter study of the safety, efficacy, and pharmacokinetics of intravenous recombinant coagulation Factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-X...
    Medical condition: Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10060612 Hemophilia A LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male
    Trial protocol: DE (Completed) FR (Completed) IE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) SE (Completed) HU (Completed) NL (Completed) IT (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-022716-39 Sponsor Protocol Number: DX-88/26 Start Date*: Information not available in EudraCT
    Sponsor Name:Dyax Corp.
    Full Title: A 3-Part Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Subcutaneous Ecallantide in Prepubertal Paediatric Patients Experiencing Acute Attacks of Hereditary Angioedema
    Medical condition: Hereditary Angioedema
    Disease: Version SOC Term Classification Code Term Level
    12.1 10019860 Hereditary angioedema LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-014796-51 Sponsor Protocol Number: 120BC201 Start Date*: 2010-02-02
    Sponsor Name:Biogen Idec Ltd.
    Full Title: Phase 2a, open-label, randomized, noncomparative study of BIIB021 in combination with exemestane in women with hormone receptor-positive, advanced metatatic breast cancer who have progressed on a n...
    Medical condition: Advanced Metastatic Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    12.0 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-006009-85 Sponsor Protocol Number: 1 Start Date*: 2012-06-04
    Sponsor Name:VU University medical center
    Full Title: Prediction of response to kinase inhibitors based on protein phosphorylation profiles in tumor tissue from advanced renal cell cancer patients
    Medical condition: Advanced solid tumors
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002215-22 Sponsor Protocol Number: LTS16294 Start Date*: 2021-06-03
    Sponsor Name:Bioverativ Therapeutics Inc.
    Full Title: A Phase 3 open-label, multicenter study of the long-term safety and efficacy of intravenous recombinant coagulation factor VIII Fc-von willebrand factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN; BIVV...
    Medical condition: Hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10060612 Hemophilia A LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) FR (Trial now transitioned) GR (Trial now transitioned) IE (Trial now transitioned) SE (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) BG (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-000624-40 Sponsor Protocol Number: CSTI571BDE70 Start Date*: 2010-05-27
    Sponsor Name:University of Heidelberg
    Full Title: PHASE II STUDY TO EVALUATE GLIVEC (IMATINIB MESYLATE) TO INDUCE PROGRESSION ARREST IN AGGRESSIVE FIBROMATOSIS / DESMOID TUMORS NOT AMENABLE TO SURGICAL RESECTION WITH R0 INTENT OR ACCOMPANIED BY UN...
    Medical condition: AGGRESSIVE FIBROMATOSIS / DESMOID TUMORS
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-003262-13 Sponsor Protocol Number: CSL627_3001 Start Date*: 2014-09-30
    Sponsor Name:CSL Behring GmbH
    Full Title: A Phase III Open Label, Multicenter, Extension Study to Assess the Safety and Efficacy of Recombinant Coagulation Factor VIII (rVIII-SingleChain, CSL627) in Subjects with Severe Hemophilia A
    Medical condition: Hemophilia A Severe hemophilia A
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004850 10060613 Hemophilia A (Factor VIII) LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male
    Trial protocol: IT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) CZ (Completed) HU (Completed) ES (Completed) NL (Completed) AT (Completed) PL (Completed) PT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2021-001693-33 Sponsor Protocol Number: ITL-2002-CL-001 Start Date*: 2022-03-30
    Sponsor Name:Intellia Therapeutics, Inc.
    Full Title: Phase 1/2 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NTLA-2002 in Adults with Hereditary Angioedema (HAE)
    Medical condition: Hereditary Angioedema
    Disease: Version SOC Term Classification Code Term Level
    23.1 10010331 - Congenital, familial and genetic disorders 10019860 Hereditary angioedema PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) FR (Trial now transitioned) DE (Trial now transitioned) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-001675-11 Sponsor Protocol Number: 0468E5-4439-WW Start Date*: 2008-02-27
    Sponsor Name:Wyeth Pharmaceuticals
    Full Title: A Randomised, Placebo Controlled, Double-Blinded Comparative Study Evaluating the Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Translplant Patients Converted to Sirolimus
    Medical condition: Prophylaxis of organ rejection in renal allograft recipients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050436 Prophylaxis against renal transplant rejection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Completed) BE (Completed) AT (Completed) DE (Completed) IT (Prematurely Ended) HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-005044-40 Sponsor Protocol Number: PPL-1021 Start Date*: 2006-01-26
    Sponsor Name:Aerovance, Inc
    Full Title: A Phase 2a Study To Investigate The Effects Of AER 002 On Mucociliary Clearance In Subjects With Chronic Obstructive Pulmonary Disease (COPD)
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003830-17 Sponsor Protocol Number: ACH228-110 Start Date*: 2020-09-16
    Sponsor Name:Achillion Pharmaceuticals, Inc., a wholly owned subsidiary of Alexion Pharmaceuticals Inc.
    Full Title: A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of the Oral Factor D (FD) Inhibitor ACH-0145228 in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patient...
    Medical condition: Paroxysmal Nocturnal Hemoglobinuria (PNH)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038359 - Renal and urinary disorders 10034042 Paroxysmal nocturnal haemoglobinuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-003459-12 Sponsor Protocol Number: CE1226_4001 Start Date*: 2006-01-30
    Sponsor Name:CSL Behring GmbH
    Full Title: A Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase III/IV Study to compare the Efficacy and Safety of 60 mg/kg body weight of Zemaira® weekly i.v. administration with Placebo weekly ...
    Medical condition: Chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004850 10001811 Alpha-1 proteinase inhibitor deficiency LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) DE (Completed) FI (Completed) EE (Completed) SE (Completed) CZ (Completed) DK (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2008-000654-12 Sponsor Protocol Number: CE1145_1001 Start Date*: 2008-09-01
    Sponsor Name:Fachbereich Medizin der Johann Wolfgang Goethe-Universität Frankfurt/M.
    Full Title: PHARMACOKINETIC BERINERT P STUDY OF SUBCUTANEOUS VERSUS INTRAVENOUS ADMINISTRATION IN SUBJECTS WITH MODERATE HEREDITARY ANGIOEDEMA - THE PASSION STUDY
    Medical condition: Patients with hereditary angioedema (HAE) suffer from recurring and mostly unforeseeable attacks of acute oedema of subcutaneous tisses of various organs. The pathophysiological correlate of this d...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-003097-41 Sponsor Protocol Number: EFC14335 Start Date*: 2017-02-20
    Sponsor Name:Sanofi-aventis recherche & développement
    Full Title: A Phase 3 Randomized, Open-label, Multicenter Study Comparing Isatuximab (SAR650984) in Combination with Pomalidomide and Low-dose Dexamethasone versus Pomalidomide and Low-dose Dexamethasone in Pa...
    Medical condition: Haematological malignancy
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10035226 Plasma cell myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) HU (Completed) PT (Completed) ES (Completed) CZ (Completed) NO (Completed) GB (GB - no longer in EU/EEA) SK (Completed) BE (Completed) DK (Completed) FR (Ongoing) GR (Completed) DE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-003436-13 Sponsor Protocol Number: 105RC101 Start Date*: 2016-05-24
    Sponsor Name:TRACON Pharmaceuticals, Inc.
    Full Title: A RANDOMIZED PHASE 2 TRIAL OF AXITINIB AND TRC105 VERSUS AXITINIB ALONE (INCLUDING A LEAD-IN PHASE 1B DOSE-ESCALATION PORTION) IN PATIENTS WITH ADVANCED OR METASTATIC RENAL CELL CARCINOMA
    Medical condition: ADVANCED OR METASTATIC RENAL CELL CARCINOMA
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10050513 Metastatic renal cell carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Prematurely Ended) PL (Completed) CZ (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 09 16:14:39 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA